Drostanolone propionate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Drostanolone propionate
Accession Number
DB14655
Description
Not Available
Type
Small Molecule
Groups
Approved, Illicit
Structure
Thumb
Weight
Average: 360.538
Monoisotopic: 360.266445019
Chemical Formula
C23H36O3
Synonyms
  • 17β-Hydroxy-2α-methyl-5α-androstan-3-one propionate
  • 2M-DHTP
  • 2MDTP
  • 2α-Methyl-4,5-dihydrotestosterone propionate
  • Blackburn Compound
  • Dromostanolone propionate
  • Emdisterone
  • Testosterone, 4,5α-dihydro-2α-methyl-, propionate
External IDs
  • Re 346
  • RS 1567

Pharmacology

Indication

For use in females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Dromostanolone is a synthetic androgen, or male hormone, similar to testosterone. Dromostanolone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells.

Mechanism of action

Dromostanolone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, dromostanolone binds to the androgen receptor. This causes downstream genetic transcriptional changes. This ultimately causes retention of nitrogen, potassium, and phosphorus; increases protein anabolism; and decreases amino acid catabolism. The antitumour activity of dromostanolone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.

Absorption

Well absorbed following parenteral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabDrostanolone propionate may increase the anticoagulant activities of Abciximab.
AcenocoumarolDrostanolone propionate may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidDrostanolone propionate may increase the anticoagulant activities of Acetylsalicylic acid.
AlteplaseDrostanolone propionate may increase the anticoagulant activities of Alteplase.
AncrodDrostanolone propionate may increase the anticoagulant activities of Ancrod.
AnistreplaseDrostanolone propionate may increase the anticoagulant activities of Anistreplase.
Antithrombin AlfaDrostanolone propionate may increase the anticoagulant activities of Antithrombin Alfa.
Antithrombin III humanDrostanolone propionate may increase the anticoagulant activities of Antithrombin III human.
ApixabanDrostanolone propionate may increase the anticoagulant activities of Apixaban.
ArdeparinDrostanolone propionate may increase the anticoagulant activities of Ardeparin.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
International/Other Brands
Drolban (Lilly) / Masteril (Syntex) / Masteron (Recordati)

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androgens and derivatives / 3-oxo-5-alpha-steroids / Cyclic ketones / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
3-oxo-5-alpha-steroid / 3-oxosteroid / Aliphatic homopolycyclic compound / Androgen-skeleton / Androstane-skeleton / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic ketone / Hydrocarbon derivative
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
steroid ester (CHEBI:31523)

Chemical Identifiers

UNII
X20UZ57G4O
CAS number
521-12-0
InChI Key
NOTIQUSPUUHHEH-UXOVVSIBSA-N
InChI
InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1
IUPAC Name
(1S,3aS,3bR,5aS,8R,9aS,9bS,11aS)-8,9a,11a-trimethyl-7-oxo-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl propanoate
SMILES

References

General References
Not Available
KEGG Drug
D01534
ChemSpider
194604
ChEBI
31523
ChEMBL
CHEMBL1201048
ZINC
ZINC000004213057
PharmGKB
PA164760855
Wikipedia
Drostanolone_propionate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000631 mg/mLALOGPS
logP4.76ALOGPS
logP5.1ChemAxon
logS-5.8ALOGPS
pKa (Strongest Basic)-6.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.37 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity101.96 m3·mol-1ChemAxon
Polarizability43.19 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on September 01, 2018 18:01 / Updated on June 12, 2020 10:53

Logo pink
Improve the accuracy of your
Precision Medicine software.
DrugBank's structured data is collected, curated and updated daily by our team of pharmacists, pharmacologists and medical doctors. Learn More.